| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
TRANSLATIONAL AND CLINICAL RESEARCH |
B-Fc Prevents Bone Loss in Ovariectomized Mice
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea
Key Words. Receptor activator of nuclear factor-
B • Receptor activator of nuclear factor-B-Fc • Mesenchymal stem cell • Gene therapy • Osteoporosis • Ovariectomy
Correspondence: Chan Soo Shin, M.D.,Department of Internal Medicine, Seoul National University College of Medicine, 28 Yungun-Dong, Chongno-Gu, Seoul 110-744, Korea. Telephone: +82-2-2072-3734; Fax: +82-2-765-3734; email: csshin{at}snu.ac.kr
Received on September 30, 2005;
accepted for publication on March 16, 2006.
First published online in STEM CELLS EXPRESS March 23, 2006.
 |
ABSTRACT |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionDisclosuresAcknowledgmentsReferences |
|---|
B-Fc (RANK-Fc), a fusion protein that specifically blocks receptor activator of nuclear factor ligand binding to RANK, has been known to be efficient and well tolerated in animal models of osteoporosis. Here we show that cell-based gene therapy with RANK-Fc effectively prevented bone loss in ovariectomized (OVX) mice. Thirty-one young adult female C57Bl/6 mice were used, and repeated intraperitoneal injection of mesenchymal stem cells (MSCs) transduced with retrovirus was performed as follows: 1) Sham-operated mice (n = 8); 2) OVX mice treated with phosphate-buffered saline (OVX-PBS; n = 8); 3) OVX mice injected with MSCs transduced with control retrovirus (OVX-green fluorescent protein [GFP]; n = 7); and 4) OVX mice injected with MSCs transduced with RANK-Fc (OVX-RANK-Fc; n = 8). Cellular expression of RANK-Fc was confirmed by Western blot analysis of cell lysates and conditioned medium and also by enzyme-linked immunosorbent assay for the mice serum. Measurement of bone mineral density (BMD) by dual-energy x-ray absorptiometry (PIXImus) revealed that the OVX-RANK-Fc group gained significantly higher BMD than either the OVX-PBS group or OVX-GFP group after 8 weeks. The expression of GFP, which is coexpressed with RANK-Fc, was detected by polymerase chain reaction analysis of DNA isolated from femur and intra-abdominal fat, whereas no GFP signal was identified in liver, brain, heart, lung, or bone marrow aspirates. These suggest that expression of RANK-Fc by genetically modified MSCs may be a feasible option for the prevention of bone loss induced by ovariectomy.
|
INTRODUCTION |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresAcknowledgmentsReferences |
|---|
Osteoclasts, the bone-resorbing cells in the bone marrow environment, are derived from the hematopoietic macrophage system through the interactions between the receptor activator of the nuclear factor-B ligand (RANKL)/RANK system (reviewed in ref. [5]). RANKL, a transmembrane molecule located on bone marrow stromal cells and osteoblasts, binds to RANK present on the surface of osteoclast precursors. This ligand-receptor interaction activates NF-B, which in turn stimulates the differentiation of osteoclast precursors to osteoclasts. Osteoprotegerin (OPG) produced by osteoblasts and stromal cells binds to RANKL, sequestering and preventing it from binding to RANK, which results in inhibition of osteoclast formation and survival [6–8]. Animals with null mutations of the OPG gene exhibit severe osteoporosis [9], whereas overexpression of OPG in transgenic mice and OPG treatment of normal rodents leads to profound osteopetrosis [6]. Mice with ablated RANKL or RANK genes exhibit osteopetrosis, impaired tooth eruption, and lymph node agenesis [10, 11], whereas RANK activation by administration of RANKL or stimulatory RANK antibodies promotes osteoclastogenesis [7, 8]. The critical role of RANKL/RANK/OPG in osteoclastogenesis has led to the development of a new therapeutic strategy, targeting this system. For example, administration of a soluble OPG or inhibitory RANK antibodies blocks osteoclastogenesis and prevents bone loss in animal models of ovariectomy-associated estrogen deficiency [6], arthritis [12], and osteolytic metastasis [13]. Moreover, results from the first human trial with OPG support its potential as a therapeutic agent for osteoporosis and bone metastasis [14, 15]. RANK-Fc is a recombinant protein of the extracellular domain of RANK fused to the Fc region of human IgG and functions as a soluble antagonist against RANKL [16]. Fusion of RANK to IgG Fc dictates homodimerization, which probably increases its avidity for RANKL. Addition of RANK-Fc in vitro virtually eliminates the formation of osteoclasts in cocultures of myeloma bone marrow and osteoblast/stromal cells [17], and transgenic mice overexpressing RANK-Fc have severe osteopetrosis because of a reduction in osteoclasts, similar to OPG transgenic mice [7]. In addition, subcutaneous injection of RANK-Fc protein into rapidly growing young mice (aged 3–4 weeks) resulted in a dose-dependent increase in total bone density as compared with control group [7]. The RANK-Fc has the potential advantage over OPG of greater specificity for RANKL.
The introduction of RANK-Fc via MSCs could be an option that could in theory overcome a number of conventional problems of recombinant protein technology, including complexity of purification, unstable biological activity, antibody formation, toxicity, and the need for frequent administration due to short half-life. These problems may be solved using gene delivery to express the targeted protein [18]. This study was undertaken to test whether introduction of the MSCs genetically modified with a retrovirus engineered to express mouse RANK-Fc could prevent the bone loss induced by ovariectomy in mice.
|
MATERIALS AND METHODS |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresAcknowledgmentsReferences |
|---|
Retroviral Vector Construction
The pMT-RANK-Fc vector containing a DNA sequence encoding the extracellular domain of mouse RANK (Met1-Pro213) fused via a linker to the Fc region of human immunoglobulin G1 (IgG1) was provided by Dr. Jaerang Rho (Chungnam National University, Daejon, Korea) and has been described previously [17]. To investigate the functional effects of sustained RANK-Fc on bone resorption, a retroviral vector encoding RANK-Fc was generated by introducing the RANK-Fc cDNA into the EcoRI/NotI site of p-murine stem cell virus-internal ribosome entry site-enhanced green fluorescent protein (plasmid [p]MSCV-IRES-eGFP) (pMSCV-eGFP, a kind gift from Dr. Ronald L. Johnson, University of Alabama at Birmingham, Birmingham, AL) [19] downstream of the MSCV long terminal repeat (LTR) and upstream of the IRES-eGFP cassette (Fig. 1), thereby allowing expression of both RANK-Fc and eGFP from a single bicistronic mRNA. The resulting construct was designated pMSCV-RANK-Fc-IRES-eGFP (pMSCV-RANK-Fc-eGFP; Fig. 1). In this system, gene expression is under the transcriptional control of MSCV LTR. The nucleotide sequence of the RANK-Fc coding region was confirmed by sequencing.
|
-minimum essential medium (MEM; Sigma-Aldrich, St. Louis, http://www.sigmaaldrich.com) supplemented with 10% fetal bovine serum (FBS; Cambrex, Walkersville, MD, http://www.cambrex.com), 2 mM L-glutamine, and 100 U/ml penicillin/100 µg/ml streptomycin (Invitrogen, Grand Island, NY, http://www.invitrogen.com). Cells were filtered through a 70-µm nylon filter (Falcon, Franklin Lakes, NJ), centrifuged for 5 minutes at 260g, suspended, and plated out in complete Dulbecco’s modified Eagle’s medium-high glucose (DMEM; Invitrogen) containing 15% horse serum (Invitrogen), 15% fetal calf serum (Invitrogen), 2 mM L-glutamine, 10–4 M 2-mercaptoethanol (Sigma-Aldrich), 10–6 M hydrocortisone (Sigma-Aldrich), and 100 U/ml penicillin-100 µg/ml streptomycin, at a density of 1 x 106 nucleated cells per ml in 25-cm2 culture flasks (Techno Plastic Products AG, Trasadingen, Switzerland). Cells were grown in complete medium at 37°C at 5% CO2 for 7 days, and the medium was replaced every 2–3 days. Adherent cells were grown to 90% confluence, washed with phosphate-buffered saline (PBS), and incubated with 0.25% trypsin/2 mM EDTA (Invitrogen). Nondetached cells were discarded, and the remaining cells were designated passage 1 (P1). Confluent MSCs were passaged further and plated at a dilution of 1:2 to 1:3. P2 to P5 MSCs were transduced with retrovirus.
Establishment of MSCs Overexpressing RANK-Fc
To obtain the viral supernatant, 293T packaging cells were transfected with the retroviral construct using Lipofectamine PLUS (Invitrogen). Briefly, 24 hours prior to transfection, 5 x 106 293T cells were plated in 100-mm dishes containing DMEM supplemented with 10% FBS and 100 U/ml penicillin-100 µg/ml streptomycin. The transfection solution contained DNA (4 µg of pMD-gag-pol, 4 µg of pMD-VSVG, and 4 µg of retroviral vector pMSCV-eGFP or pMSCV-RANK-Fc-eGFP alone), Lipofectamine PLUS, and serum-free DMEM. The medium was replaced after 3 hours. Viral supernatant fractions were collected at 48 hours, filtered through a 0.45-µm syringe filter (Nalgene, Rochester, NY), and stored at –80°C.
MSCs were plated on six-well plates at a density of 1.5 x 105 cells per well, 24 hours prior to retroviral transduction. The culture medium was removed, and retroviral supernatant (MSCV-eGFP or MSCV-RANK-Fc-eGFP) with polybrene (Sigma-Aldrich) at a final concentration of 4 µg/ml was added to the culture. Culture plates were centrifuged at 2,800 rpm at 32°C for 90 minutes and incubated at 37°C for 2 hours. A second round of infection was performed as described above, and the retrovirus supernatant was replaced with culture medium for overnight incubation. Following the third and fourth rounds of infection, cells were cultured until near confluency. Transduced cells were directly evaluated for GFP expression using a standard fluorescent microscope (Olympus IX70) and flow cytometry with a fluorescence-activated cell sorter (FACS) (FACS Vantage SE; Becton, Dickinson and Company, Franklin Lakes, NJ, http://www.bd.com) at 530 ± 30 nm.
Expression of RANK-Fc In Vitro
To assess the cellular expression of RANK-Fc, Western blot analysis was performed using cell lysates from MSCs transduced with MSCV-RANK-Fc-eGFP or empty MSCV-eGFP retrovirus as described previously [20]. Briefly, cell lysates were prepared as follows: cells were treated with lysis buffer (150 mM NaCl, 50 mM Tris-Cl, pH 7.4, 20 mM EDTA, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, and protease inhibitors), fractionated by SDS-polyacrylamide gel electrophoresis (10% gels), and transferred to nitrocellulose membranes. Blots were probed with goat polyclonal anti-mouse RANK antibody (0.1 µg/ml) or goat polyclonal anti-human IgG Fc
fragment-specific antibody (1:1,000; Jackson Laboratory, Bar Harbor, ME, http://www.jax.org), followed by horseradish peroxidase (HRP)-conjugated polyclonal anti-goat IgG (1:3,000; Santa Cruz Biotechnology Inc., Santa Cruz, CA, http://www.scbt.com) and detected by enhanced chemiluminescence using an enhanced chemiluminescence kit (Amersham Biosciences, Piscataway, NJ, http://www.amersham.com), according to the manufacturer’s instructions.
For assaying RANK-Fc secretion in vitro, serum-free DMEM was added to confluent plates of MSCs transduced with MSCV-RANK-Fc-eGFP or MSCV-eGFP. After 24 hours, culture supernatants were incubated at 4°C overnight with goat polyclonal anti-mouse RANK antibody (1 µg/ml; R&D Systems), followed by a 4°C overnight incubation with 20 µl of the agarose conjugate suspension (protein A/G-agarose; Santa Cruz Biotechnology Inc.). Samples were centrifuged at 2,500 rpm for 30 seconds at 4°C, and the supernatant was aspirated. Next, pellets were washed three times and suspended with 40 µl of 2x electrophoresis sample buffer. Samples were boiled for 5 minutes and then subjected to Western blot analysis using anti-mouse RANK antibody or anti-human IgG Fc fragment-specific antibody as above.
Experimental Design
Mice were randomly divided into four groups as follows: 1) Sham-operated mice (SHAM; n = 8); 2) OVX mice treated with PBS (OVX-PBS; n = 8); 3) OVX mice injected with MSCs transduced with control retrovirus (OVX-GFP; n = 7); and 4) OVX mice injected with MSCs transduced with RANK-Fc (OVX-RANK-Fc; n = 8). Bilateral ovariectomy in mice is a standard method to evaluate agents that ameliorate bone loss associated with estrogen deficiency [21]. On study day –1, mice were anesthetized with ketamine (50 mg/kg) and xylazine (15 mg/kg) to allow exposure of the ovaries. Specifically, the gonads were removed in OVX groups but only manipulated in the SHAM cohorts. To determine whether prophylactic treatment with RANK-Fc prevents ovariectomy-induced bone loss in an osteoporosis model, animals underwent repeated intraperitoneal injection of the indicated doses of transduced cells (OVX-GFP, OVX-RANK-Fc) or PBS (SHAM, OVX-PBS) on days 0, 2, 4, and 6.
Transduced MSCs were trypsinized, centrifuged, and suspended at a concentration of 1 x 107 nucleated cells per milliliter of PBS. Suspensions of transduced MSCs were intraperitoneally injected into C57Bl/6 mice in a total volume of 0.2 ml. Intraperitoneal injections were repeated every other day for a total of four doses, based on a previous study [22]. Sera were collected on the indicated days. Blood samples from retro-orbital capillaries were taken under anesthesia with diethyl ether (Duksan Chemical, Duksan, Korea), and serum was recovered by centrifugation at 8,000g for 10 minutes. Samples were stored at –80°C until analysis.
Bone Mineral Density Measurement
Bone mineral density (BMD) and body composition were measured using a Lunar PIXImus densitometer (software version 2.0; GE Lunar, Madison, WI) on indicated days. PIXImus scanner is a proven device for bone mineral and body composition measurements of mice and other small animals weighing 10–50 g. PIXImus acquires images in less than 5 minutes with dual-energy x-ray absorptiometry (DEXA). Mice were anesthetized with a mixture of ketamine (50 mg/kg) and xylazine (15 mg/kg) in PBS and placed prone on the platform of the PIXImus, and whole body bone mineral content (BMC; mg) and areal BMD (g/cm2) with the exclusion of head was acquired with mouse-specific software (version 1.47). Basically, BMD is calculated by dividing the BMC by projected body area. Body fat content can be also obtained by the same software. All DEXA scans were conducted by the same researcher (D.K.). Percent coefficient of variation of BMC and BMD for the repeated scans was 1%–2%.
Expression of RANK-Fc In Vivo
For enzyme-linked immunosorbent assay (ELISA), 96-well microplates were coated with goat polyclonal anti-mouse RANK antibody (1 µg/well) overnight at 4°C, washed three times with PBS-Tween (0.5% Tween 20 per liter, pH 7.4), and incubated at room temperature with blocking solution (1.59% Na2CO3, 2.93% NaHCO3, 0.2% NaN3, 1% BSA, 5% sucrose) for 1–2 hours. Wells were washed, incubated overnight at 4°C with RANK-Fc protein standard prepared in Sf9 cells (a kind gift from Dr. Jaerang Rho, Chungnam National University, Daejeon, Korea) [17] and diluted culture supernatant or mouse serum samples (100 µl); rewashed; and treated with HRP-conjugated goat anti-human IgG Fc fragment-specific antibody (1:5,000; Jackson Laboratory) for 2–4 hours. Plates were washed and incubated at room temperature with substrate solution (tetramethylbenzidine base; Sigma-Aldrich) for 20 minutes. Following the addition of stop solution (1 M H2SO2), the optical density of each well was determined using a microplate reader set (ThermoMax; Scientific Surplus, Belle Mead, NJ) at 450 nm.
DNA PCR for GFP
Femurs from sacrificed mice were dissected free of surrounding tissue and fixed in 4% paraformaldehyde-PBS (pH 7.4 with 10 N NaOH) at 4°C for 3 days. Soft tissues (liver, brain, heart, lung, and intra-abdominal fat) were dissected and placed in paraformaldehyde overnight. Bone marrow cells were isolated from the femur and tibia by inserting a 27-gauge needle into the shaft of the bone and flushing with 1 ml of -minimum essential medium as described above. To detect GFP by polymerase chain reaction (PCR), tissues and bone marrow cells were placed in a lysis buffer containing 100 mM NaCl, 100 mM Tris-Cl (pH 8.0), 25 mM EDTA (pH 8), 0.5% sodium dodecyl sulfate, and 0.1 mg/ml proteinase K. The bones were homogenized, and then lysis buffer was added. DNA was extracted from the resultant fluid by incubating in a 50°C incubator overnight, followed by addition of a phenol:chloroform mixture (1:1) to layer out the DNA from the organic phase. The supernatant of this solution was combined with 10 mM ammonium acetate, and the DNA was precipitated out with 7.3 ml of 100% ethanol per ml of sample, centrifuged, washed in 70% ethanol, and suspended in Tris:EDTA buffer.
PCR was performed using 2 µl of template DNA, 20 pmol of each primer (synthesized by Bioneer Corp., Chungwon, Korea), 200 µM dNTPs, 1 mM MgCl2, and 1 U of Taq polymerase in a 50-µl reaction volume containing 1x Taq polymerase buffer using a Perkin-Elmer Gene Amp PCR System 2400. The sense and antisense primers, 5'-CACATGAAGCAGCACGACTT-3' and 5'-AGTTCACCTTGATGCCGTTC-3', were used to amplify GFP-producing bands of 265 base pairs (bp).
Statistical Methods
Data were assessed using Statistical Package for the Social Sciences (SPSS) software (version 11.0) and summarized with descriptive statistics (mean and standard error). The differences between the four treatment groups at each time point were analyzed with the nonparametric Kruskal-Wallis test. All tests were two-sided, and a significance level of 5% was assigned.
|
RESULTS |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresAcknowledgmentsReferences |
|---|
To confirm the cellular expression of RANK-Fc, protein isolated from lysates of transduced MSCs were subjected to Western blot analysis using antibodies against mouse RANK or human IgG Fc. As shown in Figure 2A and 2B, cells transduced with the pMSCV-RANK-Fc-eGFP vector overexpressed RANK-Fc, compared with those infected with pMSCV-eGFP. Moreover, to confirm the extracellular secretion of RANK-Fc, we analyzed the culture medium of MSCs overexpressing RANK-Fc by immunoprecipitation-Western blot analysis. Immunoblots disclosed RANK-Fc protein secretion in medium from cells transduced with MSCV-RANK-Fc-eGFP, but no immunoreactivity was observed in conditioned medium from cells transduced with MSCV-eGFP (Fig. 2C, 2D).
|
|
|
|
Detection of GFP Expression by PCR
We next tested whether the bone-protective effect of RANK-Fc was a result of engraftment of RANK-Fc producing cells into bone. To address this, PCR analysis for GFP was performed using genomic DNA isolated from various tissues or bone marrow aspirates. As shown in Figure 5A, expected GFP DNA fragment (
265 bp) was weakly but clearly amplified from femur and intra-abdominal fat of OVX-RANK-Fc mice, whereas tissues from OVX+PBS group did not reveal any positive signal (Fig. 5B). DNA isolated from liver, brain, heart, lung, or bone marrow aspirates did not give a positive band in either of the two groups. Essentially the same pattern of GFP expression (i.e., only from femur and fat tissue) was also observed from OVX+GFP mice (data not shown). These results suggest that some degree of engraftment to bone has occurred after systemic injection of retrovirus-transduced MSCs, although a comparable amount of expression was also observed in fat tissue.
|
|
DISCUSSION |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresAcknowledgmentsReferences |
|---|
MSCs attract considerable attention in efforts to develop cell and gene therapies [2, 22, 23] since they are readily obtained from the patient, thus avoiding any immune responses. Additionally, extensive experiments over several decades disclose no evidence of tumorgenicity that is prominently observed with embryonic stem cells [24]. Promising results have been reported on the use of MSCs or closely related cells from bone marrow in animal models for a number of diseases, including osteogenesis imperfecta [22], Parkinsonism [25], spinal cord injury [26], stroke [27], myelin deficiency [28], cardiac disorders [29], and lung diseases [30].
Our data demonstrate that mesenchymal cell-based gene therapy with RANK-Fc has clearly protected bone loss associated with ovariectomy in C57Bl/6 mice. Effects on bone density are small, however, possibly due to the rapid skeletal growth of the mice that renders the evaluation of a "bone-protective" effect difficult in this rodent OVX model. In our study, the circulating level of RANK-Fc peaked at 1 week after the last injection, consistent with previous data [31], and decreased gradually over 2 months. The durability of expression of the desired gene is a major limitation of retroviral transduction of MSCs. No report has extended beyond 4 months post-transplantation of transduced cells [3, 31]. In most instances, expression decreases with time [32] due to promoter inactivation [33] and/or loss of transduced cells. Although these results are promising, they highlight the need for careful consideration of ex vivo methods, choice of promoter to direct the desired biological activity, and assessment of the self-maintenance of transduced MSCs upon in vivo transplantation.
It remains a matter of controversy whether donor-derived MSCs are capable of homing and engraftment into the marrow cavity following transplantation. A number of reports indicate that marrow-derived cells engraft as differentiated cells into multiple tissues following infusion into experimental animals [2, 22, 23], whereas others suggest that MSCs do not engraft in marrow after systemic infusion [34, 35]. In our experiments, GFP signals were observed in bone and intra-abdominal fat, but not from any other tissues, including bone marrow aspirates by PCR analysis. The presence of GFP signal from intra-abdominal fat seems to be a consequence of intraperitoneal injection of cells resulting in initial accumulation of a large number of cells locally. Our finding of positive PCR bands from femur but not from freshly isolated bone marrow cells is intriguing. One can speculate that the injected cells engrafted, differentiated, or moved, and then resided within the bone tissue, such as bony lacunae or lining cells. However, we have not traced the migration of cells directly, nor were we able to identify the cell types that express GFP using sensitive assays, such as fluorescent in situ hybridization. Therefore, the positive PCR results from femur do not definitely prove the engraftment of donor cells. In addition, the cells we used as a vehicle were not isolated by specific selection method using cell surface markers, and introducing retrovirus by multiple rounds of transduction may have resulted in alteration of stem cell characteristics, including the capacity for homing. Indeed, in our study, the therapeutic effects of RANK-Fc could have been obtained regardless of the location of the transplanted cells once they are connected to the systemic circulation. To confirm whether the systemically administered cells have engrafted, in situ immunological analysis will be required in our model.
MSCs are easily isolated from iliac crest bone marrow aspirates. The systemic infusion of autologous MSCs appears to be well tolerated in a Phase I clinical trial [36]. Additionally, several reports suggest that engraftment of whole marrow or MSCs is possible in mice or dogs without the need for marrow ablation, provided that cells are infused in large numbers or at regularly spaced intervals [37, 38]. Accordingly, it may be possible to use gene-engineered MSCs from patients for therapy of common diseases, such as osteoporosis, in which marrow ablation cannot be justified. However, notwithstanding the potential benefits of MSC as a cellular vehicle to convey therapeutic gene product, strategies to overcome the risks imposed by retroviral transduction, that is, uncontrolled proliferation and even tumor formation, which can occur depending on the integration of the virus, should be developed before any clinical application could be tried.
The main limitation of our study is that by using mice in a growing phase, it is difficult to directly extrapolate our results to postmenopausal or involutional model of osteoporosis. Indeed, the role of the RANK/OPG system in the growing mice has not been well established. Moreover, since BMD measurement using DEXA is significantly affected by the size of the bones, interpreting the changes in BMD in animals of different size is very complicated [39, 40]. Nonetheless, our results are consistent with the study by Hsu et al. who demonstrated in vivo bone protective effects of RANK-Fc in immature growing mice (aged 3–4 weeks) [7].
In summary, genetically modified MSCs are capable of sustaining to secrete RANK-Fc up to 8 weeks after intraperitoneal injection, and RANK blockade by RANK-Fc may be an effective method to prevent ovariectomy-induced bone loss. These data support the use of bone marrow-derived MSCs as cellular vehicles for gene therapy and pave the way for a future therapeutic approach for osteoporosis using genetically modified MSCs.
|
DISCLOSURES |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresAcknowledgmentsReferences |
|---|
|
ACKNOWLEDGMENTS |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresAcknowledgmentsReferences |
|---|
|
REFERENCES |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionDisclosuresAcknowledgmentsReferences |
|---|
This article has been cited by other articles:
|
|
 |
|
  F. Lamoureux, G. Picarda, J. Rousseau, C. Gourden, S. Battaglia, C. Charrier, B. Pitard, D. Heymann, and F. Redini Therapeutic efficacy of soluble receptor activator of nuclear factor-{kappa}B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma Mol. Cancer Ther., October 1, 2008; 7(10): 3389 - 3398. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| STEM CELLS | THE ONCOLOGIST | CME | ALPHAMED PRESS JOURNALS |
